Zelrix™: A Novel Transdermal Formulation of Sumatriptan

  title={Zelrix{\texttrademark}: A Novel Transdermal Formulation of Sumatriptan},
  author={Mark W. Pierce and Thomas C. Marbury and Carol O'neill and Steven J. Siegel and Wei Du and Terri B. Sebree},
  journal={Headache: The Journal of Head and Face Pain},
Objective.— This study evaluated the pharmacokinetic and tolerability profiles of Zelrix™ (NuPathe Inc., Conshohocken, PA, USA), the novel formulation of sumatriptan (formerly known as NP101). 
Twelve‐Month Tolerability and Efficacy Study of NP101, the Sumatriptan Iontophoretic Transdermal System
Objective.— To assess the long‐term tolerability and efficacy of NP101, a novel transdermal sumatriptan patch being developed for the acute treatment of migraine.
Transdermal Sumatriptan for Acute Treatment of Migraineurs With Baseline Nausea
Evaluation of the efficacy and safety of transdermal sumatriptan in migraine patients who have baseline nausea in patients with baseline nausea finds it to be safe and effective.
Subcutaneous Sumatriptan Pharmacokinetics: Delimiting the Monoamine Oxidase Inhibitor Effect
  • A. Fox
  • Medicine, Biology
  • 2010
(Headache 2010;50:249‐255)
The iontophoretic transdermal system formulation of sumatriptan as a new option in the acute treatment of migraine: a perspective
According to pharmacokinetic properties and clinical data, sumatriptan ITS may be a good choice for people with migraine and severe nausea, vomiting or gastroparesis, those with intolerable triptan-related adverse events and those not responding optimally to oral medications.
Sumatriptan Iontophoretic Transdermal System Reduces Treatment‐Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline – Results From a Randomized Controlled Trial
To test the hypothesis that sumatriptan iontophoretic transdermal system (TDS) is associated with lower rates of treatment‐emergent nausea (TEN) relative to placebo, as well as to compare the
Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine
This evaluation specifically reviews the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of different formulations and dosages of sumatriptan used for the acute treatment of migraines.
Sumatriptan Transdermal System Can Be Correctly Assembled and Applied During Migraine Attacks
The objective of this study was to validate the ease of assembly and application of the sumatriptan iontophoretic transdermal system (sumatriptan TDS, Zecuity®, NuPathe, Inc., Malvern, PA, USA)
A Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine
The sumatriptan iontophoretic transdermal system uses proprietary technology to circumvent the gastrointestinal tract while delivering triptan therapy for the acute treatment of migraine.
Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice
The new drug formulations that are the most similar to the pharmacokinetics parameters of the subcutaneous sumatriptan are promising because they both improve pharmacokinetic bioavailability bypassing the first-pass metabolism and increase patient compliance.


A Unique Iontophoretic Patch for Optimal Transdermal Delivery of Sumatriptan
This study met the initial objective to define the dose–current relationship in humans as well as delimiting specific current and current density targets for a well tolerated patch design that can deliver therapeutic drug levels for longer periods than currently possible.
Bioequivalence and Rapid Absorption of Zolmitriptan Nasal Spray Compared with Oral Tablets in Healthy Japanese Subjects
The rapid absorption of zolmitriptan nasal spray may explain the faster relief from migraine reported in patients compared with oral zolMITriptan.
Migraine Prevalence and Treatment Patterns: The Global Migraine and Zolmitriptan Evaluation Survey
The objectives of the Migraine And Zolmitriptan Evaluation survey were to understand migraineurs' experience of migraine and its management on a global level, and to assess patient perceptions and preferences of current and future treatment formulations.
Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine
The fixed-dose single-tablet formulation of sumatriptan/naproxen was effective and well tolerated in an early intervention paradigm for the acute treatment of migraine, including traditional and nontraditional symptoms.
Gastric Stasis in Migraine: More Than Just a Paroxysmal Abnormality During a Migraine Attack
The aim of this article is to evaluate gastric motility and emptying in the ictal and interictal period in migraine.
The Pharmacology of the Novel 5-HT1-Like Receptor Agonist, GR43175
Its vasoconstrictor action can be shown to be localized even further to arteriovenous anastomoses (shunts) within the carotid circulation, in such a way that blood flow to the brain as well as to extracerebral capillary beds remains unaffected or may even be increased.
Defeating migraine pain with triptans: A race against the development of cutaneous allodynia
The probability of consistent pain‐free outcome increases drastically if triptan therapy is vigilantly timed to precede any signs of cutaneous allodynia, a phenomenon that develops gradually during the course of the migraine attack.
5-HT1-like receptors: a time to bid goodbye.
Migraine Symptoms: Results of a Survey of Self‐Reported Migraineurs
The most common reported symptoms associated with migraine were pain, nausea, problems with vision, and vomiting, and the most important features of a migraine medication were rapid and effective relief of headache pain, decreasing the likelihood of headache recurrence, and not causing nausea.